Looking Into Recursion Pharmaceuticals's Recent Short Interest
Portfolio Pulse from Benzinga Insights
Recursion Pharmaceuticals (NYSE:RXRX) has seen a significant rise in short interest, with 27.68% of its float sold short, compared to a peer average of 13.52%. This indicates increased bearish sentiment, although it doesn't guarantee a price drop.
September 16, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Recursion Pharmaceuticals has experienced a notable increase in short interest, now at 27.68% of its float, which is significantly higher than its peers' average of 13.52%. This suggests a bearish market sentiment towards the stock.
The increase in short interest to 27.68% of float suggests that investors are bearish on Recursion Pharmaceuticals, as it is significantly higher than the peer average of 13.52%. This could lead to downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100